Clinical Trials
6 trialsNCT06392386 2026-06-04
ADAPT Jr SC
argenx
Phase 2/3 Recruiting
NCT06193889 2026-05-15
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting
NCT06055959 2026-05-08
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06149559 2026-05-08
roMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06447597 2026-04-30
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3 Recruiting
NCT05374590 2026-04-23
ADAPT Jr +
argenx
Phase 2/3 Enrolling by invitation